Literature DB >> 10666378

Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

S E Stoltzner1, T J Grenfell, C Mori, K E Wisniewski, T M Wisniewski, D J Selkoe, C A Lemere.   

Abstract

The complement system constitutes a series of enzymatic steps involved in the inflammatory response and is activated in Alzheimer's disease (AD). Using Down's syndrome (DS) brains as a temporal model for the progression of AD, we examined components of the complement cascade and their relationship to other principal events in AD pathology: Abeta42 deposition, neuritic changes, neurofibrillary tangles (NFTs), and gliosis (reactive astrocytes, activated microglia). Adjacent sections of frontal cortex from 24 DS subjects ranging in age from 12 to 73 years were immunohistochemically examined for immunoreactivity (IR) of classical complement proteins (Clq and C3), markers indicating activation of complement (C4d and C5b-9), the complement inhibitor apolipoprotein J (apo J), and markers of AD neuropathology. Abeta42-labeled diffuse plaques were first detected in a 12-year-old DS subject and were not labeled by any of the complement antibodies. Colocalization of Abeta42 with Clq, C3, C4d, and/or apo J was first detected in compacted plaques in the brain of a 15-year-old DS patient with features of mature AD pathology, such as reactive astrocytes, activated microglia, dystrophic neurites, and a few NFTs. IR for C4d and C5b-9 (membrane attack complex, MAC) was observed in small numbers of plaque-associated dystrophic neurites and in focal regions of pyramidal neurons in this 15-year-old. The only other young (</=30 years) DS brain to show extensive complement IR was that of a 29-year-old DS subject who also displayed the full range of AD neuropathological features. All middle-aged and old DS brains showed IR for Clq and C3, primarily in compacted plaques. In these cases, C4d IR was found in a subset of Abeta42 plaques and, along with C5b-9 IR, was localized to dystrophic neurites in a subset of neuritic plaques, neurons, and some NFTs. Our data suggest that in AD and DS, the classical complement cascade is activated after compaction of Abeta42 deposits and, in some instances, can progress to the local neuronal expression of the MAC as a response to Abeta plaque maturation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666378      PMCID: PMC1850044          DOI: 10.1016/S0002-9440(10)64753-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease.

Authors:  K S Kosik; C L Joachim; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

Review 2.  Tau mutations cause frontotemporal dementias.

Authors:  M Goedert; R A Crowther; M G Spillantini
Journal:  Neuron       Date:  1998-11       Impact factor: 17.173

Review 3.  Translating cell biology into therapeutic advances in Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

4.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.

Authors:  I Grundke-Iqbal; K Iqbal; M Quinlan; Y C Tung; M S Zaidi; H M Wisniewski
Journal:  J Biol Chem       Date:  1986-05-05       Impact factor: 5.157

5.  Inhibition of respiratory burst in macrophages by complement receptor blockade.

Authors:  A Klegeris; P L McGeer
Journal:  Eur J Pharmacol       Date:  1994-08-01       Impact factor: 4.432

6.  Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study.

Authors:  P Eikelenboom; F C Stam
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

7.  Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain.

Authors:  P L McGeer; D G Walker; H Akiyama; T Kawamata; A L Guan; C J Parker; N Okada; E G McGeer
Journal:  Brain Res       Date:  1991-03-29       Impact factor: 3.252

8.  Up-regulated production and activation of the complement system in Alzheimer's disease brain.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

9.  Complement activation by cross-linked truncated and chimeric full-length beta-amyloid.

Authors:  D H Cribbs; P Velazquez; B Soreghan; C G Glabe; A J Tenner
Journal:  Neuroreport       Date:  1997-11-10       Impact factor: 1.837

10.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome.

Authors:  K E Wisniewski; H M Wisniewski; G Y Wen
Journal:  Ann Neurol       Date:  1985-03       Impact factor: 10.422

View more
  61 in total

Review 1.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

Review 2.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 3.  Microglia and inflammation in Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.

Authors:  Qiaoqiao Shi; Saba Chowdhury; Rong Ma; Kevin X Le; Soyon Hong; Barbara J Caldarone; Beth Stevens; Cynthia A Lemere
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

5.  Innate immune network in the retina activated by optic nerve crush.

Authors:  Justin P Templeton; Natalie E Freeman; John M Nickerson; Monica M Jablonski; Tonia S Rex; Robert W Williams; Eldon E Geisert
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-09       Impact factor: 4.799

6.  Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Authors:  Marcel Maier; Ying Peng; Liying Jiang; Timothy J Seabrook; Michael C Carroll; Cynthia A Lemere
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

7.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

Review 8.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

9.  Brain ischemia and ischemic blood-brain barrier as etiological factors in sporadic Alzheimer's disease.

Authors:  Ryszard Pluta; Marzena U Amek
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

10.  Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains.

Authors:  Stéphanie Baulac; Hope Lu; Jennifer Strahle; Ting Yang; Matthew S Goldberg; Jie Shen; Michael G Schlossmacher; Cynthia A Lemere; Qun Lu; Weiming Xia
Journal:  Mol Neurodegener       Date:  2009-02-25       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.